Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities

Accrued Liabilities

12 Months Ended

Dec. 31, 2019

Accrued Liabilities and Other Liabilities [Abstract]

Accrued liabilities consisted of the following:



	December 31,
	2019		2018
Salaries, benefits and related expenses	$	1,098	$	2,446
Device warranty	285		255
Clinical trials	203		227
Financing lease liability	18		35
Severance	—		270
Other	79		256
Total	$	1,683	$	3,489

Warranty

Sales of devices generally include an initial warranty for parts and services for one year in the U.S., two years in Europe, the Middle East, Africa, and one or two years in Asia. A liability for the estimated cost of product warranty is established at the time revenue is recognized based on the historical experience of known product failure rates and expected material and labor costs to provide warranty services. Specific additional warranty accruals may be made if unforeseen technical problems arise. Alternatively, if estimates are determined to be greater than the actual amounts necessary, a portion of the liability may be reversed in future periods. Warranty costs are reflected in the consolidated statements of operations and comprehensive loss as a component of costs of revenue. The current portion of the warranty liability is classified as a component of accrued liabilities, while the long-term portion of the warranty liability is classified as a component of other non-current liabilities in the consolidated balance sheets.



	Warranty
	2019			2018
Balance at beginning of the period	$	319		$	232
Additions for estimated future expense	416			374
Incurred costs	(385		)	(287		)
Balance at end of the period	$	350		$	319

Current portion	285			255
Long-term portion	65			64
Total	$	350		$	319